This subgroup analysis from an ongoing prospective study evaluates whether intraoperative in-vivo HSI enables rapid estimation of MGMT promoter methylation, potentially offering a practical, time-efficient tool for personalized decision-making in glioma surgery. This evidence concerns the gene MGMT and central nervous system cancer.